Loading…
Strength and functional mobility in children with acute lymphoblastic leukemia
Background The purposes of this pilot study were as follows: (1) to evaluate tools for measuring neuropathy in children with acute lymphoblastic leukemia (ALL), (2) to examine strength and functional mobility in children with ALL, and (3) to determine if there is a relationship between strength and...
Saved in:
Published in: | Medical and pediatric oncology 2003-04, Vol.40 (4), p.230-232 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background
The purposes of this pilot study were as follows: (1) to evaluate tools for measuring neuropathy in children with acute lymphoblastic leukemia (ALL), (2) to examine strength and functional mobility in children with ALL, and (3) to determine if there is a relationship between strength and function.
Procedure
Strength of knee extension and ankle dorsiflexion as measured with a dynamometer and functional mobility with the Timed Up and Go (TUG) were examined in eight children with ALL, ages 4–15 years, before and during delayed intensification (DI) therapy and in age‐ and gender‐matched controls.
Results
The mean knee extension strength, ankle dorsiflexion strength, and TUG measures for children with ALL before DI were significantly less than the means for the controls. The mean dorsiflexion strength measures for the children with ALL afte4 weeks of DI therapy were significantly lower than at time zero. Correlation of −0.794 (P = 0.05) was found between knee extension strength and TUG score for children with ALL.
Conclusions
The dynamometer and TUG are reliable tools to measure strength and function in children with ALL early in their treatment. In this study, ankle dorsiflexion strength worsened during DI therapy. There was a correlation between strength and function in children with ALL. Med Pediatr Oncol 2003;40:230–232. © 2003 Wiley‐Liss, Inc. |
---|---|
ISSN: | 0098-1532 1096-911X |
DOI: | 10.1002/mpo.10266 |